R

Research Institute of Dallas | Dallas, TX

Research site

(Unclaimed)

Location

10260 N Central Expressway, Suite 100 N, Dallas, Texas, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

Bococizumab

Dapagliflozin

Tirzepatide

Teplizumab

Metformin

Octreotide

BMS-512148

Paltusotine

LY3298176

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 44 total trials

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting

Type 2 Diabetes Mellitus

Drug: Tirzepatide

Drug: Dulaglutide

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)

The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52...

Enrolling

Central Precocious Puberty

Drug: Debio 4326

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM202...

Active, not recruiting

Acromegaly

Drug: CAM2029 (octreotide subcutaneous depot)

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi...

Active, not recruiting

Prader-Willi Syndrome

Drug: DCCR